NAYA NAYA Biosciences Inc: רווח למניה לשנה מתגלגלת

The primary driver for NAYA Biosciences is the precision international delivery of oncology therapy components, which supports high margins. The year-over-year change in EPS (TTM) illustrates this trend, where the 0.00 level captures the latest values. The robotization of cell analysis accelerates drug discovery, while independence from macroeconomic factors transforms the company into a resilient defensive asset.
פילוחי מדדים פיננסיים ומדדי שוק עבור NAYA Biosciences Inc (NAYA)

For NAYA Biosciences, which develops cancer immunotherapy methods, this indicator assesses the effectiveness of monetizing its developments. The metric measures the annual change in earnings per share, revealing the impact of operating expenses on final profitability. The current YoY net income per share growth over the last 12 months is 0.00. This chart reflects the risks of international clinical trial disruptions due to geopolitics. Negative values signal rising costs for biomaterials.